Daniel Costin, MD

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Daniel Costin, MD, hematology and oncology, White Plains Hospital, discusses the potential with immunotherapy agents in the frontline setting as treatment for patients with non–small cell lung cancer (NSCLC).